Pricing Strategy in Life Sciences: Moving Beyond Cost-Plus to Value-Based Models

Cost-plus pricing is the default in life sciences. It is easy to calculate, easy to defend internally, and easy to explain to customers. It is also, in most cases, a significant source of margin leakage — because it prices products based on what they cost to make, not on what they are worth to the buyer.

Value-based pricing starts from a different question: what is the economic value of this product to the customer? For a research reagent that enables a critical assay, the value is not the cost of the raw materials — it is the cost of the research program that depends on it. For a diagnostic test that enables earlier disease detection, the value is not the cost of the consumables — it is the downstream healthcare cost that earlier detection avoids.

The transition from cost-plus to value-based pricing requires three organizational capabilities that most life sciences companies have not fully developed.

First, customer value quantification. This means understanding, with specificity, how customers use the product, what outcomes it enables, and what the economic value of those outcomes is. This requires customer research — not satisfaction surveys, but deep conversations about workflows, decision criteria, and the cost of alternatives.

Second, segmented pricing architecture. Different customer segments derive different value from the same product. A value-based pricing model captures this variation through tiered pricing, volume structures, or application-specific pricing that reflects the different value contexts of different buyers.

Third, value communication capability. A value-based price is only defensible if the organization can articulate the value it represents. This requires sales and marketing teams who can quantify customer value in customer terms — not in terms of product specifications, but in terms of research outcomes, operational efficiency, or clinical impact.

Organizations that make this transition consistently find that their actual price realization increases — not because they have raised prices arbitrarily, but because they have aligned their pricing with the value they genuinely deliver.